SECOND ANNUAL MEETING OF THE NATIONAL COOPERATIVE VACCINE DEVELOPMENT GROUPS FOR AIDS, OCTOBER 15-18, 1989, FORT LAUDERDALE, FL NLM AIDSLINE Important note: Information in this article was accurate in 1990. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


SECOND ANNUAL MEETING OF THE NATIONAL COOPERATIVE VACCINE DEVELOPMENT GROUPS FOR AIDS, OCTOBER 15-18, 1989, FORT LAUDERDALE, FL

Second Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS. October 15-18, 1989, Fort Lauderdale, FL, Vaccine Research and Development Branch, Division of AIDS, NIAID, 1989.. Unique Identifier : AIDSLINE ICDB/90649240
Anonymous; No affiliation given

Abstract: The second annual meeting of the National Cooperative Vaccine Development Groups (NCVDGs) for AIDS was held October 15-18, 1989, in Fort Lauderdale, Florida. Topics included the HIV genome: opportunity/obstacles for AIDS vaccine development; the HIV Vaccine Consortium; idiotype-based vaccines for controlling HIV infection; correlates of immunity; NCVDG projects I and II, biologic and immunologic strategies; the European Community AIDS Vaccine Program; vaccines as immunotherapeutics; simian immunodeficiency virus (SIV) recombinant antigens; mapping of immunogenic epitopes in HIV proteins and their incorporation into novel synthetic and live-vector-based vaccines; mucosal and systemic immunity to SIV and HIV vaccines; adjuvants and immuno-stimulating complexes; CD4 requirement for antibody-dependent enhancement of HIV-1 infection via Fc receptors; development of an AIDS prototype vaccine using SIV; retroviral vector and synthetic peptide approaches to AIDS vaccines; guidelines for vaccine clinical trials; safety and immunogenicity of an HIV-1 recombinant gp160 candidate vaccine in humans; update of NIAID intramural gp160; HIV-1 gp160 expressed by vaccinia; safety and immunogenicity of a genetically engineered candidate HIV vaccine; progress in the development of HGP-30, an HIV-P17-based AIDS vaccine; a multistrategy approach to the control of HIV infection and/or disease; and a pilot study of anti-leu3a in patients with AIDS-related complex. Workshops on humoral and cellular immune responses, genetic variation, the SIV model, and chimpanzee studies provided a forum for the review of current data and for planning priorities and future directions for research.
Keywords: Acquired Immunodeficiency Syndrome/*IMMUNOLOGY/PREVENTION & CONTROL Animal Chimpansee troglodytes Clinical Trials Gene Products, env/IMMUNOLOGY Human HIV/*IMMUNOLOGY HIV Antibodies/BIOSYNTHESIS HIV Antigens/IMMUNOLOGY HIV-1/IMMUNOLOGY SIV/IMMUNOLOGY Vaccines, Synthetic/ADMINISTRATION & DOSAGE/*IMMUNOLOGY Viral Vaccines/ADMINISTRATION & DOSAGE/*IMMUNOLOGY CLINICAL TRIAL MONOGRAPHKWDacquiredimmunodeficiencysyndrome/KWDimmunology/prevention&controlanimalchimpanseetroglodytesclinicaltrialsgeneproducts,env/immunologyhumanhiv/KWDimmunologyhivantibodies/biosynthesishivantigens/immunologyhiv-1/immunologysiv/immunologyvaccines,synthetic/administration&dosage/KWDimmunologyviralvaccines/administration&dosage/KWDimmunologyclinicaltrialmonograph
901230
M90C3741

Copyright © 1990 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1990. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1990. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .